10:00 AM EST - Medicenna Therapeutics Corp. : Announced today that updated clinical data from the ongoing Phase 1/2 ABILITY-1 study will be presented as part of an oral podium presentation at the 2024 Immunotherapy Bridge Conference, taking place from December 4-5, in Naples, Italy. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.02 at $1.79.
